AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. AELIX Therapeutics is a spin-off of IrsiCaixa, coming from the HIVACAT program. IrsiCaixa is a Catalan public-private consortium conducting cutting-edge research in the field of AIDS and related diseases. The company was incorporated in November 2015 and completed a €11.5M ($12.5M) Series A funding shortly thereafter through funds managed by Ysios Capital, a Spanish investment firm, Johnson & Johnson Innovation – JJDC, Inc., and Caixa Capital Risc, the venture capital division of Spain’s leading financial group, ‘la Caixa’.